Diabetes patients on empagliflozin show improved heart risk factors

07/3/2013 | InternalMedicineNews.com (free registration)

Empagliflozin was associated with significant improvements in cardiovascular risk factors, A1C rates and body weight at 24 weeks in type 2 diabetes patients, data presented at the ADA 73rd Scientific Sessions indicated. Researchers also found that among patients with uncontrolled blood pressure at baseline, 33.3% of those who took empagliflozin at 10 mg/day and 32.2% of those who took 25 mg/day had regulated blood pressure at week 24, compared with 18.6% in the placebo group.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC